Naloxone.
Narcotic analgesics and related drugs act as agonists on several receptors that are responsible for their effects on pain perception, mood and feeling state, and respiration, as well as other pharmacologic actions. Naloxone is the first discovered antagonist that is devoid of agonistic activity and appears to be a competitive antagonist at several receptors. The ability of naloxone to displace or prevent the binding of agonistic narcotics is partly responsible for its antagonistic effects. The ability of naloxone to rectify narcotic-depressed homeostats and precipitate abstinence is also related to its antagonistic activity. Certain cautions and principles apply in the use of naloxone in treating narcotic overdose, reversing surgical analgesia, and the treatment of neonates and children. Unapproved uses of naloxine include reversing the psychotomimetic effects of certain agonists-antagonists, terminating narcotic-induced convulsions and coma, reversing non-narcotic depression, diagnosing physical dependence, and treating narcotic addicts.
D000328:Adult; D000700:Analgesics / Q000037:antagonists & inhibitors; D000818:Animals; D002648:Child; D003128:Coma / Q000188:drug therapy; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D051379:Mice; D009270:Naloxone / Q000494:pharmacology / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D009294:Narcotics / Q000506:poisoning; D011247:Pregnancy; D011957:Receptors, Opioid / Q000187:drug effects; D012128:Respiratory Distress Syndrome / Q000188:drug therapy; D012640:Seizures / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000534:rehabilitation
D000700:Analgesics; D009292:Narcotic Antagonists; D009294:Narcotics; D011957:Receptors, Opioid; D009270:Naloxone